Treatment of giant cell arteritis – current approach and new possibilities

Česká verzia

Authors: Jakub Videman; Martina Skácelová; Pavel Horák; Adéla Skoumalová; Dominik Hraboš
Authors place of work: III. interní klinika – nefrologická, revmatologická a endokrinologická, FN a LF UP Olomouc
Published in the journal: Vnitř Lék 2022; 68(5): 266-272
Category: Main Topic
doi: https://doi.org/10.36290/vnl.2022.058

Summary

Giant Cell Arteritis (GCA) is an autoimmune mediated systemic vasculitis affecting large arteries – the aorta and its branches. It has the highest incidence of all systemic vasculitides and manifests nearly exclusively in patients aged 50 or older. Amongst its non-specific and specific symptoms are headaches, mastication claudication or signs of rheumatic polymyalgia, a relatively common and immediate treatment requiring condition being acute vision loss due to optic ischemia. A GCA diagnosis is based on clinical and paraclinical findings and imaging techniques including PET/CT; with an important role still being played by histological verification from temporal artery biopsy. Treatment is based on immunosuppressive agents – systemic glucocorticoids, with adjunct therapy options being methotrexate and tocilizumab. Currently, there are also several clinical trials examining the efficacy of other modern biological agents in GCA.

Keywords:

Methotrexate – glucocorticoids – giant cell arteritis – tocilizumab

Zdroje

1. Gonzalez‑Gay MA, Vazquez‑Rodriguez TR, Lopez‑Diaz MJ et al. Epidemiology of giant cell arteritis and polymyalgia rheumatica. Arthritis Rheum. 2009;61(10):1454.

2. Salvarani C, Hunder GG. Giant cell arteritis with low erythrocyte sedimentation rate: frequency of occurence in a population‑based study. Arthritis Rheum. 2001;45(2):140.

3. Roche NE, Fulbright JW, Wagner AD et al. Correlation of interleukin-6 production and disease activity in polymyalgia rheumatica and giant cell arteritis. Arthritis Rheum. 1993;36(9):1286.

4. Sammel AM, Hsiao E, Schembri G et al. Diagnostic Accuracy of Positron Emission Tomography/ Computed Tomography of the Head, Neck, and Chest for Giant Cell Arteritis: A Prospective, Double‑Blind, Cross‑Sectional Study. Arthritis Rheumatol. 2019 Aug;71(8):1319-1328.

5. Schmidt WA. Ultrasound in the diagnosis and management of giant cell arteritis. Rheumatology (Oxford). 2018 Feb 1;57(suppl_2):ii22-ii31.

6. Hellmich B, Agueda A, Monti S, et al. 2018 Update of the EULAR recommendations for the management of large vessel vasculitis. Ann. Rheum. 2020;79:19-30.

7. Aiello PD, Trautmann JC, McPhee TJ et al. Visual prognosis in giant cell arteritis. Ophthalmology. 1993;100(4):550.

8. Mahr AD, Jover JA, Spiera RF et al. Adjunctive methotrexate for treatment of giant cell arteritis: an individual patient data meta‑analysis. Arthritis Rheum. 2007 Aug;56(8):2789-97.

9. De Boysson H, Boutemy J, Creveuil C et al. Is there a place for cyclophosphamide in the treatment of giant‑ cell arteritis? A case series and systematic review. Semin Arthritis Rheum. 2013;43(1):105.

10. Villiger PM, Adler S, Kuchen S et al. Tocilizumab for induction and maintenance of remission in giant cell arteritis: A phase 2, randomised, double‑blind, placebo‑ controlled trial. Lancet. 2016;387(10031):1921.

11. Unizony S, Arias‑Urdaneta L, Miloslavsky E et al. Tocilizumab for the treatment of large‑vessel vasculitis (giant cell arteritis, Takayasu arteritis) and polymyalgia rheumatica. Arthritis Care Res (Hoboken). 2012 Nov;64(11):1720-9.

12. Hoffman GS, Cid MC, Rendt‑Zagar KE et al. Infliximab for maintenance of glucocorticosteroid‑ induced remission of giant cell arteritis: a randomized trial. Ann Intern Med. 2007;146(9):621.

13. Schmidt WA, Dasgupta B, Luqmani R et al. A Multicentre, Randomised, Double‑Blind, Placebo‑Controlled, Parallel‑Group Study to Evaluate the Efficacy and Safety of Sirukumab in the Treatment of Giant Cell Arteritis. Rheumatol Ther. 2020 Dec;7(4):793-810.

14. Langford CA, Cuthbertson D, Ytterberg SR et al. A Randomized, Double‑Blind Trial of Abatacept (CTLA-4Ig) for the Treatment of Giant Cell Arteritis. Arthritis Rheumatol. 2017;69(4):837.

15. Conway R, O‘Neill L, Gallagher P et al. Ustekinumab for refractory giant cell arteritis: A prospective 52-week trial. Semin Arthritis Rheum. 2018 Dec;48(3):523-528.

16. Cid MC, Unizony SH, Blockmans D et al. Efficacy and safety of mavrilimumab in giant cell arteritis: a phase 2, randomised, double‑blind, placebo‑ controlled trial. Ann Rheum, DiS. 2022 May;81(5):653-661.